TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Misoprostol for Preventing Postpartum Hemorrhage
Brief Summary: This hospital-based, multicenter, randomized, placebo-controlled trial will assess the effects of misoprostol as part of active management of the third stage of labor on postpartum blood loss, complications, and side effects. Twelve hundred eligible women will receive routine oxytocics (oxytocin 5-10 IU) plus either 400 mcg sublingual misoprostol or placebo during or immediately after delivery. The primary outcome will be measured blood loss of =\>500 mls within one hour after enrollment.


Options:
A: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
C: Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): N/A
D: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Misoprostol for Preventing Postpartum Hemorrhage
Brief Summary: This hospital-based, multicenter, randomized, placebo-controlled trial will assess the effects of misoprostol as part of active management of the third stage of labor on postpartum blood loss, complications, and side effects. Twelve hundred eligible women will receive routine oxytocics (oxytocin 5-10 IU) plus either 400 mcg sublingual misoprostol or placebo during or immediately after delivery. The primary outcome will be measured blood loss of =\>500 mls within one hour after enrollment.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
B: Arm Label: Carbetocin; Type: N/A; Interventions: N/A | Arm Label: Oxytocin; Type: N/A; Interventions: N/A
C: Arm Label: Syntocinon; Type: ACTIVE_COMPARATOR; Interventions: Drug: Syntocinon | Arm Label: Carbetocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Syntocinon; Assigned to Arm(s): Syntocinon | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol
D: Arm Label: Carbetocin 80mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 90mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 110mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 120mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 80mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 90mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 100mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 110mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 120mcg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Misoprostol for Preventing Postpartum Hemorrhage
Brief Summary: This hospital-based, multicenter, randomized, placebo-controlled trial will assess the effects of misoprostol as part of active management of the third stage of labor on postpartum blood loss, complications, and side effects. Twelve hundred eligible women will receive routine oxytocics (oxytocin 5-10 IU) plus either 400 mcg sublingual misoprostol or placebo during or immediately after delivery. The primary outcome will be measured blood loss of =\>500 mls within one hour after enrollment.


Options:
A: Arm Label: Syntocinon; Type: ACTIVE_COMPARATOR; Interventions: Drug: Syntocinon | Arm Label: Carbetocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Syntocinon; Assigned to Arm(s): Syntocinon | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol
B: Arm Label: Short infusion; Type: EXPERIMENTAL; Interventions: Drug: Carbetocin Short-infusion | Arm Label: Bolus application; Type: OTHER; Interventions: Drug: Carbetocin Bolus application | Intervention Type: DRUG; Name: Carbetocin Short-infusion; Assigned to Arm(s): Short infusion | Intervention Type: DRUG; Name: Carbetocin Bolus application; Assigned to Arm(s): Bolus application
C: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: UnijectTM; Type: EXPERIMENTAL; Interventions: Device: UnijectTM | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DEVICE; Name: UnijectTM; Assigned to Arm(s): UnijectTM
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Potential for Diet Modification to Improve Glycaemic Control and Cardiovascular Risk Factors Over and Above Drug Therapy in Type 2 Diabetes at High Risk of Cardiovascular Disease
Brief Summary: In the past, nutritional management formed the cornerstone of treatment of type 2 diabetes (T2DM). More recently, this aspect of treatment has received less attention as drug therapy aimed not only to lower glucose, but also to treat raised blood pressure and blood fats (including cholesterol) has been more widespread. While there is evidence to suggest that blood pressure and blood fat levels have improved, overall diabetes control has not and people with diabetes appear to be becoming progressively more overweight, following trends in the general population. The proposed study involves a randomised controlled trial in which people with T2DM continuing with their regular drug treatment and surveillance, will be randomly allocated to additionally receive intensive advice regarding diet or remain on their usual treatment in this regard. The results will be judged principally in terms of body weight, waist circumference, blood pressure, blood glucose control and blood fats.


Options:
A: Arm Label: High MUFA diet; Type: EXPERIMENTAL; Interventions: Other: High-MUFA diet | Arm Label: High CHO diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High-CHO diet | Intervention Type: OTHER; Name: High-MUFA diet; Assigned to Arm(s): High MUFA diet | Intervention Type: OTHER; Name: High-CHO diet; Assigned to Arm(s): High CHO diet
B: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Intensive dietary advice; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Mono Unsaturated Fatty Acids in Obesity; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Potential for Diet Modification to Improve Glycaemic Control and Cardiovascular Risk Factors Over and Above Drug Therapy in Type 2 Diabetes at High Risk of Cardiovascular Disease
Brief Summary: In the past, nutritional management formed the cornerstone of treatment of type 2 diabetes (T2DM). More recently, this aspect of treatment has received less attention as drug therapy aimed not only to lower glucose, but also to treat raised blood pressure and blood fats (including cholesterol) has been more widespread. While there is evidence to suggest that blood pressure and blood fat levels have improved, overall diabetes control has not and people with diabetes appear to be becoming progressively more overweight, following trends in the general population. The proposed study involves a randomised controlled trial in which people with T2DM continuing with their regular drug treatment and surveillance, will be randomly allocated to additionally receive intensive advice regarding diet or remain on their usual treatment in this regard. The results will be judged principally in terms of body weight, waist circumference, blood pressure, blood glucose control and blood fats.


Options:
A: Intervention Type: BEHAVIORAL; Name: Intensive dietary advice; Assigned to Arm(s): N/A
B: Intervention Type: DIETARY_SUPPLEMENT; Name: Peanuts and peanut butter; Assigned to Arm(s): N/A
C: Arm Label: Walnut Ad libitum diet; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnut Ad libitum diet | Arm Label: Walnut Calorie Controlled; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnut Calorie controlled | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnut Ad libitum diet; Assigned to Arm(s): Walnut Ad libitum diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnut Calorie controlled; Assigned to Arm(s): Walnut Calorie Controlled
D: Arm Label: Consumption of 42 g of salted peanuts; Type: EXPERIMENTAL; Interventions: Other: Consumption of 42 grams of peanuts daily | Arm Label: Consumption of 42 g of unsalted peanuts; Type: EXPERIMENTAL; Interventions: Other: Consumption of 42 grams of peanuts daily | Arm Label: Consumption of 42 g of spicy peanuts; Type: EXPERIMENTAL; Interventions: Other: Consumption of 42 grams of peanuts daily | Arm Label: Consumption of 42 g of honey peanuts; Type: EXPERIMENTAL; Interventions: Other: Consumption of 42 grams of peanuts daily | Arm Label: Consumption of 42 g of 3 diff. varieties; Type: EXPERIMENTAL; Interventions: Other: Consumption of 42 grams of peanuts daily | Arm Label: Consumption of 42 g of var. of types; Type: EXPERIMENTAL; Interventions: Other: Consumption of 42 grams of peanuts daily | Intervention Type: OTHER; Name: Consumption of 42 grams of peanuts daily; Assigned to Arm(s): Consumption of 42 g of 3 diff. varieties, Consumption of 42 g of honey peanuts, Consumption of 42 g of salted peanuts, Consumption of 42 g of spicy peanuts, Consumption of 42 g of unsalted peanuts, Consumption of 42 g of var. of types

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Potential for Diet Modification to Improve Glycaemic Control and Cardiovascular Risk Factors Over and Above Drug Therapy in Type 2 Diabetes at High Risk of Cardiovascular Disease
Brief Summary: In the past, nutritional management formed the cornerstone of treatment of type 2 diabetes (T2DM). More recently, this aspect of treatment has received less attention as drug therapy aimed not only to lower glucose, but also to treat raised blood pressure and blood fats (including cholesterol) has been more widespread. While there is evidence to suggest that blood pressure and blood fat levels have improved, overall diabetes control has not and people with diabetes appear to be becoming progressively more overweight, following trends in the general population. The proposed study involves a randomised controlled trial in which people with T2DM continuing with their regular drug treatment and surveillance, will be randomly allocated to additionally receive intensive advice regarding diet or remain on their usual treatment in this regard. The results will be judged principally in terms of body weight, waist circumference, blood pressure, blood glucose control and blood fats.


Options:
A: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Diet counseling; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Intensive dietary advice; Assigned to Arm(s): N/A
D: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Potential for Diet Modification to Improve Glycaemic Control and Cardiovascular Risk Factors Over and Above Drug Therapy in Type 2 Diabetes at High Risk of Cardiovascular Disease
Brief Summary: In the past, nutritional management formed the cornerstone of treatment of type 2 diabetes (T2DM). More recently, this aspect of treatment has received less attention as drug therapy aimed not only to lower glucose, but also to treat raised blood pressure and blood fats (including cholesterol) has been more widespread. While there is evidence to suggest that blood pressure and blood fat levels have improved, overall diabetes control has not and people with diabetes appear to be becoming progressively more overweight, following trends in the general population. The proposed study involves a randomised controlled trial in which people with T2DM continuing with their regular drug treatment and surveillance, will be randomly allocated to additionally receive intensive advice regarding diet or remain on their usual treatment in this regard. The results will be judged principally in terms of body weight, waist circumference, blood pressure, blood glucose control and blood fats.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Caloric Restriction; Type: OTHER; Interventions: Behavioral: behavioral dietary intervention | Arm Label: Exercise Intervention; Type: OTHER; Interventions: Behavioral: Exercise intervention | Arm Label: Caloric Restriction AND Exercise Intervention; Type: OTHER; Interventions: Behavioral: behavioral dietary intervention, Behavioral: Exercise intervention | Intervention Type: BEHAVIORAL; Name: behavioral dietary intervention; Assigned to Arm(s): Caloric Restriction, Caloric Restriction AND Exercise Intervention | Intervention Type: BEHAVIORAL; Name: Exercise intervention; Assigned to Arm(s): Caloric Restriction AND Exercise Intervention, Exercise Intervention
B: Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Intensive dietary advice; Assigned to Arm(s): N/A
D: Arm Label: Intensive therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle consultation: weight control, diet, exercise | Arm Label: Conventional therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle consultation: weight control, diet, exercise | Intervention Type: BEHAVIORAL; Name: Lifestyle consultation: weight control, diet, exercise; Assigned to Arm(s): Intensive therapy | Intervention Type: BEHAVIORAL; Name: Lifestyle consultation: weight control, diet, exercise; Assigned to Arm(s): Conventional therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Potential for Diet Modification to Improve Glycaemic Control and Cardiovascular Risk Factors Over and Above Drug Therapy in Type 2 Diabetes at High Risk of Cardiovascular Disease
Brief Summary: In the past, nutritional management formed the cornerstone of treatment of type 2 diabetes (T2DM). More recently, this aspect of treatment has received less attention as drug therapy aimed not only to lower glucose, but also to treat raised blood pressure and blood fats (including cholesterol) has been more widespread. While there is evidence to suggest that blood pressure and blood fat levels have improved, overall diabetes control has not and people with diabetes appear to be becoming progressively more overweight, following trends in the general population. The proposed study involves a randomised controlled trial in which people with T2DM continuing with their regular drug treatment and surveillance, will be randomly allocated to additionally receive intensive advice regarding diet or remain on their usual treatment in this regard. The results will be judged principally in terms of body weight, waist circumference, blood pressure, blood glucose control and blood fats.


Options:
A: Intervention Type: BEHAVIORAL; Name: Weight reduction, Resistance training, Aerobic exercise training, Control; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Intensive dietary advice; Assigned to Arm(s): N/A
C: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Arm Label: Control Group (delayed intervention); Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Intervention Type: OTHER; Name: Weight loss intervention; Assigned to Arm(s): Control Group (delayed intervention), Intervention Group
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Caloric Restriction; Type: OTHER; Interventions: Behavioral: behavioral dietary intervention | Arm Label: Exercise Intervention; Type: OTHER; Interventions: Behavioral: Exercise intervention | Arm Label: Caloric Restriction AND Exercise Intervention; Type: OTHER; Interventions: Behavioral: behavioral dietary intervention, Behavioral: Exercise intervention | Intervention Type: BEHAVIORAL; Name: behavioral dietary intervention; Assigned to Arm(s): Caloric Restriction, Caloric Restriction AND Exercise Intervention | Intervention Type: BEHAVIORAL; Name: Exercise intervention; Assigned to Arm(s): Caloric Restriction AND Exercise Intervention, Exercise Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Treatment for Schizophrenic Smokers
Brief Summary: Schizophrenic individuals are typically nicotine dependent smokers who find it difficult to quit smoking. The purpose of this study is to determine the effectiveness of bupropion SR (commonly known as Zyban) in combination with a nicotine transdermal patch (NTP), in helping schizophrenic individuals quit smoking. In addition, this study will evaluate how the combination of bupropion SR and NTP affects psychiatric symptoms and medication side effects.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion (Wellbutrin) | Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm I (varenicline); Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II (nicotine patch); Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I (varenicline) | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Arm II (nicotine patch)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Treatment for Schizophrenic Smokers
Brief Summary: Schizophrenic individuals are typically nicotine dependent smokers who find it difficult to quit smoking. The purpose of this study is to determine the effectiveness of bupropion SR (commonly known as Zyban) in combination with a nicotine transdermal patch (NTP), in helping schizophrenic individuals quit smoking. In addition, this study will evaluate how the combination of bupropion SR and NTP affects psychiatric symptoms and medication side effects.


Options:
A: Arm Label: Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo
B: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline (CP-526,555) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo Arm | Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): Treatment Arm
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2

Answer: D